Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #629 | October 23, 2015  

Stepping Out to Cure Scleroderma: Let Us Know Your Thoughts

Stepping Out Logo ResizedWe'd like to thank the thousands of participants who took part this year in our "Stepping Out to Cure Scleroderma" walk or run events. We appreciate your continued support of these special events held across the country.

We would like your feedback to help us improve next year's online experience for our participants. The survey will take approximately 15 to 20 minutes to complete. The deadline to complete the survey is 11:59 p.m. Central Time Saturday, Oct. 31, 2015. To access the survey, click the link provided in this email or visit today.

To show our appreciation, you can receive a special gift from the Foundation for providing your input. Please provide us your contact information in the fields at the end of the survey. Your gift will arrive in 4 to 6 weeks to the mailing address that you provide.

If you have any further questions, please contact Tracey O. Sperry, National Director of Research and Development, at or (800) 722-4673, Ext. 248.

Take the survey now >>

Video: What Your Dentist Wants to Know About Scleroderma

VIdeo: What Your Dentist Wants to Know

About half of the dentists responding to a survey feared that lack of knowledge might result in harm if they treated scleroderma patients. This concern reduces access to oral health care for scleroderma patients. Dr. David Leader will explain what dentists should and would like to know about scleroderma, oral health, and you. This session was recorded at the 2015 National Patient Education Conference put on by the Scleroderma Foundation.

View the entire video now >>

New Evidence for PAH Therapy Using Two Popular Medications

spilled Pills.jpgRecent studies have indicated a confirmed benefit for pulmonary arterial hypertension (PAH) for patients using two popular medications, Letairis (ambrisentan) and Cialis (tadalafil).

Severe risk factors, such as death, hospitalization and worsening disease progression, were reduced by half in one clinical trial group. Findings from the study were presented earlier this year at the American Thoracic Society's annual meeting.

Read the full story at MedPage Today >>


New Oxygen Therapy Guide from Pulmonary Hypertension Association

pha logo.jpgOur friends at the Pulmonary Hypertension Association have recently released a new online guide for oxygen therapy. Find out more about oxygen therapy, resources, and if your insurance coverage will help.

Read the full resource guide from PHA here >>

Visit PHA's full website here to learn more about their programs and resources >>

"Scleroderma Voice" - Submit Your Story Ideas

Fall 2015 Scleroderma Voice CoverOur next issue of "Scleroderma Voice," our quarterly member magazine will be due out in early 2016. Please submit your feedback or story ideas to us. We'd love to hear from you!

The deadline to submit your story ideas and comments is Tuesday, Dec. 1, 2015. Please email to with "Scleroderma Voice Ideas" in the subject line.

Learn more about our award-winning magazine here >>

Donate Button
Quick Links
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat

Actelion current web size
Bayer 2015 gold and platinum Sponsor
Gilead Silver Conference Sponsor
United Therapeutics corporate sponsor.jpg



Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2019 All rights reserved.